Albumin-based Liver Reserve Models as Prognostic Markers for Patients With Extensive-stage Small-cell Lung Cancer

Area of Science:

• Oncology
• Hepatology
• Internal Medicine

Background:

• Albumin-bilirubin (ALBI) score/grade is a validated index of hepatic functional reserve.
• ALBI score's prognostic utility has been established in various cancers.
• Its role in extensive-stage small-cell lung cancer (ES-SCLC) remains under-investigated.

Purpose of the Study:

• To evaluate the prognostic value of albumin-based liver reserve models in ES-SCLC patients.
• To assess the relationship between liver reserve indices and outcomes in ES-SCLC treated with platinum-doublet chemotherapy.

Main Methods:

• Retrospective analysis of 104 ES-SCLC patients receiving first-line platinum-doublet chemotherapy.
• Pretreatment assessment of albumin-bilirubin (ALBI), easy (EZ)-ALBI, platelet-albumin-bilirubin (PALBI), and platelet-albumin (PAL) grades.
• Statistical analysis including overall survival (OS) and multivariate analysis.

Main Results:

• Patients with low ALBI (≤-2.60) and PAL (≤-3.77) grades demonstrated significantly longer OS.
• Median OS for low ALBI grade: 351.5 days vs. high ALBI grade: 214.5 days (p=0.018).
• ALBI and PAL grades were independent prognostic factors for OS on multivariate analysis (p=0.006 and p=0.011, respectively).

Conclusions:

• Albumin-based liver reserve models, particularly ALBI and PAL grades, serve as valuable prognostic markers.
• These models can aid in predicting outcomes for ES-SCLC patients undergoing platinum-doublet chemotherapy.